Cite
Maanaoui M, Chetboun M, Top I, et al. 207.5: Impact of HLA Donor Specific Antibodies in the Era of Cell Therapy: Clinical Trajectories in Islet Allotransplantation Illustrate a Challenging Model. Transplantation. 2021;105(12):S5doi: 10.1097/01.tp.0000804296.25243.a8.
Maanaoui, M., Chetboun, M., Top, I., Kerr-Conte, J., Le Mapihan, K., Gmyr, V., Hubert, T., Labalette, M., Hazzan, M., Vantyghem, M. C., & Pattou, F. (2021). 207.5: Impact of HLA Donor Specific Antibodies in the Era of Cell Therapy: Clinical Trajectories in Islet Allotransplantation Illustrate a Challenging Model. Transplantation, 105(12), S5. https://doi.org/10.1097/01.tp.0000804296.25243.a8
Maanaoui, Mehdi, et al. "207.5: Impact of HLA Donor Specific Antibodies in the Era of Cell Therapy: Clinical Trajectories in Islet Allotransplantation Illustrate a Challenging Model." Transplantation vol. 105,12 (2021): S5. doi: https://doi.org/10.1097/01.tp.0000804296.25243.a8
Maanaoui M, Chetboun M, Top I, Kerr-Conte J, Le Mapihan K, Gmyr V, Hubert T, Labalette M, Hazzan M, Vantyghem MC, Pattou F. 207.5: Impact of HLA Donor Specific Antibodies in the Era of Cell Therapy: Clinical Trajectories in Islet Allotransplantation Illustrate a Challenging Model. Transplantation. 2021 Dec 01;105(12):S5. doi: 10.1097/01.tp.0000804296.25243.a8. PMID: 34908301.
Copy
Download .nbib